Voriconazole dispersible tablet and preparation method thereof
By using polyethylene glycol microcapsules in voriconazole dispersed tablets to wrap sodium bicarbonate and sodium carbonate and externally wrap organic acids to form a three-dimensional mesh layer structure, the stability problem of the dispersed tablets in high humidity and high temperature is solved, and the stability of the dispersed tablets is achieved. Quick release and safety of the drug.
Patent Information
- Application Number
- CN202411151029.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
Voriconazole dispersed tablets are prone to absorb water and disintegrate early in high humidity and high temperature conditions, resulting in low dissolution and deterioration of the drug, affecting drug safety.
Add polyethylene glycol microcapsules to the dispersed tablets, which encapsulate sodium bicarbonate and sodium carbonate inside and organic acid outside, and form a three-dimensional mesh layer structure through modification to adjust the carbon dioxide generation time and temperature to prevent early disintegration and deterioration .
It effectively avoids the early disintegration of dispersed tablets in high humidity environments and deterioration at high temperatures, ensures the rapid release and stability of the drug, and improves the safety and therapeutic effect of the drug.
Smart Images

Figure BDA0005003668310000011 
Figure BDA0005003668310000081 
Figure BDA0005003668310000082
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceuticals, and in particular relates to a voriconazole dispersible tablet and a preparation method thereof. Background Art
[0002] Voriconazole is a broad-spectrum triazole antifungal drug that can inhibit the activity of lanosterol 14α-demethylase and 24-methylenedihydrolanosterol demethylase in fungal cells, thereby inhibiting the synthesis of ergosterol, an important substance on the fungal cell membrane, leading to defects in the fungal cell membrane, leakage of important cell components and death. Voriconazole has a bactericidal effect on Candida and Aspergillus fungi, and also has a bactericidal effect on other pathogenic fungi.
[0003] Its chemical structure is:
[0004]
[0005] Voriconazole is currently mainly in the form of tablets, which are taken orally. It is obtained by granulating and tableting voriconazole raw materials, auxiliary materials and disintegrants. Since voriconazole has a low solubility in water and a slow dissolution rate, in order to solve this problem, acid-base materials are currently added to the tablets so that the tablets react to generate carbon dioxide when they encounter water, thereby accelerating the disintegration of the tablets to increase the solubility of the drug. However, although this method can solve the solubility problem of voriconazole dispersible tablets when they encounter water when taken, it does not consider the problem of water absorption and premature disintegration when the humidity in the environment is high during packaging, especially during storage. At the same time, impurities are easily generated in the external high temperature environment during storage and transportation, causing deterioration.
[0006] In view of this, this patent application is filed. Summary of the invention
[0007] In order to solve the above problems, the purpose of this patent application is to provide a voriconazole dispersible tablet and a preparation method thereof. By adding polyethylene glycol microcapsules to the dispersible tablets, encapsulating sodium bicarbonate and sodium carbonate inside the microcapsules and encapsulating organic acids on the outside, it can be ensured that during the packaging and storage process, the problem of premature disintegration of the dispersible tablets caused by water absorption in a high humidity environment can be avoided.
[0008] The present invention is achieved through the following technical solutions:
[0009] The first object of the present invention is to provide a voriconazole dispersible tablet, comprising the following components in parts by weight: 20 to 40 parts of voriconazole, 5 to 12 parts of a binder, 15 to 20 parts of a sweetener, 5 to 15 parts of a disintegrant, and 5 to 10 parts of polyethylene glycol microcapsules, wherein the polyethylene glycol microcapsules are encapsulated with sodium bicarbonate and sodium carbonate, and the polyethylene glycol microcapsules are encapsulated with an organic acid, wherein the ratio of the sum of the weight parts of the sodium bicarbonate and the sodium carbonate to the weight part of the organic acid is 1:(1 to 1.5), and the weight ratio of the sodium bicarbonate to the sodium carbonate is 3:1;
[0010] The organic acid outside the polyethylene glycol microcapsule is modified to form a modified product having a three-dimensional network layer structure outside the polyethylene glycol microcapsule, and the modifier is any one of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate and cellulose propionate.
[0011] In the embodiment of the present invention, polyethylene glycol microcapsules are added to the dispersible tablets, sodium bicarbonate and sodium carbonate are wrapped inside the microcapsules, and organic acid is wrapped outside the polyethylene glycol, so that it can be ensured that in the packaging and storage process, the problem of premature disintegration caused by water absorption of the dispersible tablets in a high humidity environment is avoided, and the problem of slow disintegration in the subsequent taking process is avoided. And the alkali adopts a combination of sodium bicarbonate and sodium carbonate. Since sodium bicarbonate and sodium carbonate have different reaction rate constants with organic acids, when taking the dispersible tablets, sodium bicarbonate and sodium carbonate are different from organic acid reaction rates, so that the generation time of carbon dioxide is more lasting, and the discomfort of the user caused by the instantaneous disintegration of the dispersible tablets can be alleviated. When the dispersible tablets of the present invention are taken, the capsule body of the polyethylene glycol microcapsules is dissolved in water, and the internal sodium bicarbonate and sodium carbonate contact with the organic acid outside the microcapsules to produce carbon dioxide, so that the dispersible tablets are disintegrated and release voriconazole.
[0012] Due to changes in the external environment, when drugs are stored in a high-temperature environment, it is easy to produce impurities and cause deterioration. In order to solve this problem, the polyethylene glycol microcapsule is modified in the embodiment of the present invention to form a three-dimensional network layer on the outside of the organic acid of the microcapsule. The three-dimensional network layer forms a shell-like structure on the outside of the polyethylene glycol microcapsule, and together with the organic acid outside the polyethylene glycol, the polyethylene glycol is protected. In this way, the polyethylene glycol can be used to absorb and release the external high temperature, play a role in regulating the temperature, reduce the drug's own absorption of high temperature and cause deterioration, and affect the safety of the drug.
[0013] In an optional embodiment, the binder is one or a combination of two or more of povidone, hydroxymethyl cellulose, and hydroxypropyl cellulose.
[0014] In an optional embodiment, the sweetener is stevia.
[0015] In an optional embodiment, the disintegrant is one or a combination of two or more of sodium hydroxymethyl starch, low-substituted hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone.
[0016] In an optional embodiment, the average molecular weight of the polyethylene glycol is 800-20000, and the organic acid is any one of citric acid, tartaric acid, citric acid, and fumaric acid, or a combination of two or more thereof.
[0017] The average molecular weight of the polyethylene glycol used in the embodiment of the present invention is 800-20000. Such polyethylene glycol has better solubility in water, better chemical stability, better lubrication effect, and is also beneficial to the quality of subsequent tableting.
[0018] In an optional embodiment, the polyethylene glycol is further wrapped with an internal disintegrant, the ratio of the weight of the internal disintegrant to the sum of the weight of the sodium bicarbonate and the sodium carbonate is 1:(2-3), and the internal disintegrant is one or a combination of two or more of sodium hydroxymethyl starch sodium, low-substituted hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone.
[0019] In the embodiment of the present invention, an internal disintegrant is provided inside the polyethylene glycol microcapsule. Under the dual effects of the internal disintegrant and the external disintegrant, in addition to the effect of carbon dioxide generated after contact with water, and the different reaction rates of sodium bicarbonate and sodium carbonate with organic acids, the disintegration efficiency is accelerated while avoiding the discomfort of the user, which is conducive to the rapid release of the active ingredients of the drug to meet the treatment needs.
[0020] In an optional embodiment, the diameter of the modified polyethylene glycol microcapsule having a three-dimensional network layer is 3 to 8 microns.
[0021] In an optional embodiment, the weight ratio of the modifier to the polyethylene glycol microcapsule is 1:2 to 1:3.
[0022] The second object of the present invention is to provide a method for preparing a voriconazole dispersible tablet as described in any one of the above items, comprising the following steps:
[0023] (1) micronizing the voriconazole raw material;
[0024] (2) Pass the sweetener and disintegrant through a 60-mesh sieve respectively;
[0025] (3) adding the treated voriconazole, sweetener, disintegrant, and polyethylene glycol microcapsule into a high-efficiency wet granulator according to weight ratio and mixing them evenly;
[0026] (4) adding a binder, sieving to obtain wet granules, placing in a dryer to dry, granulating, and tableting to obtain the obtained granules;
[0027] The preparation method of the polyethylene glycol microcapsule is:
[0028] According to weight parts, polyethylene glycol is heated to 50-60° C. to completely melt, and sodium bicarbonate, sodium carbonate, and an internal disintegrant are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture;
[0029] The mixture is cooled and crushed to 85-90 meshes, and then an organic acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and organic acid wrapped outside.
[0030] In an optional embodiment, polyethylene glycol microcapsules are mixed with a modifier and reacted to obtain a modified product.
[0031] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0032] (1) The present invention adds polyethylene glycol microcapsules to the dispersible tablets, wherein the microcapsules contain sodium bicarbonate and sodium carbonate and the organic acid is contained on the outside, thereby preventing the dispersible tablets from disintegrating prematurely due to water absorption in a high humidity environment during packaging and storage, and also preventing the potential safety hazard of impurity generation caused by premature disintegration.
[0033] (2) The present invention forms a three-dimensional network structure layer similar to the shell structure on the outside of the polyethylene glycol microcapsule, which protects the polyethylene glycol microcapsule from damage during packaging, transportation and storage, thereby utilizing polyethylene glycol to absorb and release the external high temperature, thereby playing a role in regulating temperature, reducing the drug's own absorption of high temperature and causing deterioration, and ensuring drug safety.
[0034] (3) The present invention adopts a base combination of sodium bicarbonate and sodium carbonate, and utilizes the different reaction rates between sodium bicarbonate and sodium carbonate and organic acid to make the generation time of carbon dioxide more lasting, and can also alleviate the discomfort of the user caused by the instantaneous disintegration of the dispersible tablet.
[0035] (4) The present invention provides an internal disintegrant inside the polyethylene glycol microcapsule. Under the dual effects of the internal and external disintegrants, coupled with the effect of carbon dioxide generated after contact with water, and the different reaction rates of sodium bicarbonate and sodium carbonate with organic acids, the disintegration efficiency is accelerated while avoiding discomfort to the user, which is beneficial to the rapid release of the active ingredients of the drug to meet the treatment needs. DETAILED DESCRIPTION
[0036] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The illustrative embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.
[0037] In the description of the present invention, terms such as "front", "rear", "left", "right", "up", "down", "vertical", "horizontal", "high", "low", "inside" and "outside" to indicate directions or positional relationships are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the referred device or element must have a specific direction, be constructed and operated in a specific direction, and therefore should not be understood as limiting the scope of protection of the present invention.
[0038] Embodiment 1:
[0039] A voriconazole dispersible tablet has the following formula: 26 parts of voriconazole, 5 parts of povidone, 18 parts of stevioside, 13 parts of cross-linked povidone, and 7 parts of polyethylene glycol microcapsules; the sum of the weight parts of sodium bicarbonate and sodium carbonate encapsulated inside the polyethylene glycol microcapsules is 7 parts, including 5.25 parts of sodium bicarbonate and 1.75 parts of sodium carbonate; and 7 parts of citric acid are encapsulated outside the polyethylene glycol microcapsules.
[0040] Prepared by the following method:
[0041] (1) micronizing the voriconazole raw material;
[0042] (2) passing stevioside and crospovidone through a 60-mesh sieve respectively;
[0043] (3) according to the weight ratio, 26 parts of the treated voriconazole, 18 parts of stevioside, 13 parts of cross-linked polyvinylpyrrolidone, and polyethylene glycol microcapsules were added into a high-efficiency wet granulator and mixed evenly;
[0044] (4) Add 5 parts of povidone to prepare a soft material, then pass through a 70-mesh sieve to prepare wet granules, place the wet granules in a dryer for drying at 60° C. for 1 hour, and granulate the granules; then place the granules in a multi-directional motion mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0045] The preparation method of polyethylene glycol microcapsules is as follows:
[0046] According to weight parts, polyethylene glycol (molecular weight 10000) is heated to 50°C to completely melt, and 3.5 parts of sodium bicarbonate, sodium carbonate and cross-linked polyvinylpyrrolidone are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture;
[0047] The mixture is cooled to room temperature, crushed to 85 meshes, and then citric acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and citric acid wrapped outside.
[0048] The method for modifying the citric acid outside the polyethylene glycol microcapsule is:
[0049] The polyethylene glycol microcapsules wrapped with the internal disintegrant are mixed with hydroxypropyl cellulose and reacted to obtain a modified product. The weight ratio of the polyethylene glycol microcapsules wrapped with the internal disintegrant to the hydroxypropyl cellulose is 2:1. The diameter of the modified polyethylene glycol microcapsules is 3 microns.
[0050] Embodiment 2:
[0051] A voriconazole dispersible tablet has the following formula: 20 parts of voriconazole, 12 parts of povidone, 20 parts of stevioside, 5 parts of cross-linked povidone, 5 parts of polyethylene glycol microcapsules, the sum of the weight parts of sodium bicarbonate and sodium carbonate encapsulated inside the polyethylene glycol microcapsules is 5 parts, including 3.75 parts of sodium bicarbonate and 1.25 parts of sodium carbonate, and 5 parts of tartaric acid are encapsulated outside the polyethylene glycol microcapsules.
[0052] Prepared by the following method:
[0053] (1) micronizing the voriconazole raw material;
[0054] (2) passing stevioside and crospovidone through a 60-mesh sieve respectively;
[0055] (3) according to the weight ratio, 20 parts of the treated voriconazole, 20 parts of stevioside, 5 parts of cross-linked polyvinylpyrrolidone, and 5 parts of polyethylene glycol microcapsules were added into a high-efficiency wet granulator and mixed evenly;
[0056] (4) 12 parts of povidone are added to prepare a soft material, which is then passed through a 70-mesh sieve to prepare wet granules. The wet granules are placed in a dryer for drying at 55° C. for 1.5 hours, and granules are obtained after being granulated. The granules are then placed in a multi-directional mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0057] The preparation method of polyethylene glycol microcapsules is as follows:
[0058] According to weight parts, polyethylene glycol (molecular weight 8000) is heated to 55° C. to completely melt, and 2.5 parts of sodium bicarbonate, sodium carbonate and cross-linked polyvinylpyrrolidone are added to the molten polyethylene glycol and mixed uniformly to obtain a mixture;
[0059] The mixture is cooled to room temperature, crushed to 90 meshes, and then tartaric acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and tartaric acid wrapped outside.
[0060] The method for modifying the tartaric acid outside the polyethylene glycol microcapsule is:
[0061] The polyethylene glycol microcapsules coated with the internal disintegrant are mixed with hydroxypropyl cellulose and reacted to obtain a modified product. The weight ratio of the polyethylene glycol microcapsules coated with the internal disintegrant to the hydroxypropyl cellulose is 3:1. The diameter of the modified polyethylene glycol microcapsules is 5 microns.
[0062] Embodiment 3:
[0063] A voriconazole dispersible tablet has the following formula: 40 parts of voriconazole, 10 parts of hydroxymethyl cellulose, 15 parts of stevioside, 15 parts of hydroxymethyl starch sodium, and 10 parts of polyethylene glycol microcapsules; the sum of the weight parts of sodium bicarbonate and sodium carbonate wrapped inside the polyethylene glycol microcapsules is 10 parts, including 7.5 parts of sodium bicarbonate and 2.5 parts of sodium carbonate; and 10 parts of citric acid are wrapped outside the polyethylene glycol microcapsules.
[0064] Prepared by the following method:
[0065] (1) micronizing the voriconazole raw material;
[0066] (2) Pass stevioside and sodium hydroxymethyl starch through a 60-mesh sieve respectively;
[0067] (3) According to the weight ratio, 40 parts of the treated voriconazole, 15 parts of stevioside, 15 parts of sodium hydroxymethyl starch, and 10 parts of polyethylene glycol microcapsules were added into a high-efficiency wet granulator and mixed evenly;
[0068] (4) 10 parts of hydroxymethyl cellulose was added to prepare a soft material, which was then passed through a 70-mesh sieve to prepare wet granules. The wet granules were placed in a dryer for drying at 55° C. for 1.5 hours, and granules were obtained after being granulated. The granules were then placed in a multi-directional mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0069] The preparation method of polyethylene glycol microcapsules is as follows:
[0070] According to weight parts, polyethylene glycol (molecular weight 8000) is heated to 60° C. to be completely melted, and 5 parts of sodium bicarbonate, sodium carbonate and cross-linked polyvinylpyrrolidone are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture;
[0071] The mixture is cooled to room temperature, crushed to 90 meshes, and then citric acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and citric acid wrapped outside.
[0072] The method for modifying the citric acid outside the polyethylene glycol microcapsule is:
[0073] The polyethylene glycol microcapsules wrapped with the internal disintegrant are mixed with hydroxypropyl cellulose and reacted to obtain a modified product. The weight ratio of the polyethylene glycol microcapsules wrapped with the internal disintegrant to cellulose acetate is 3:1. The diameter of the modified polyethylene glycol microcapsules is 8 microns.
[0074] Embodiment 4:
[0075] A voriconazole dispersible tablet has the following formula: 35 parts of voriconazole, 10 parts of hydroxypropyl cellulose, 15 parts of stevioside, 15 parts of sodium hydroxymethyl starch, and 10 parts of polyethylene glycol microcapsules; the sum of the weight parts of sodium bicarbonate and sodium carbonate wrapped inside the polyethylene glycol microcapsules is 10 parts, including 7.5 parts of sodium bicarbonate and 2.5 parts of sodium carbonate; and 10 parts of citric acid are wrapped outside the polyethylene glycol microcapsules.
[0076] Prepared by the following method:
[0077] (1) micronizing the voriconazole raw material;
[0078] (2) Pass stevioside and sodium hydroxymethyl starch through a 60-mesh sieve respectively;
[0079] (3) according to the weight ratio, 35 parts of the treated voriconazole, 15 parts of stevioside, 15 parts of sodium hydroxymethyl starch, and 10 parts of polyethylene glycol microcapsules were added into a high-efficiency wet granulator and mixed evenly;
[0080] (4) Add 10 parts of hydroxypropyl cellulose to prepare a soft material, then pass through a 70-mesh sieve to prepare wet granules, place the wet granules in a dryer for drying at 60° C. for 1 hour, and granulate the granules; then place the granules in a multi-directional motion mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0081] The preparation method of polyethylene glycol microcapsules is as follows:
[0082] According to weight parts, polyethylene glycol (molecular weight 20000) is heated to 60°C to completely melt, and 5 parts of sodium bicarbonate, sodium carbonate and cross-linked polyvinylpyrrolidone are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture;
[0083] The mixture is cooled to room temperature, crushed to 90 meshes, and then citric acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and citric acid wrapped outside.
[0084] The method for modifying the citric acid outside the polyethylene glycol microcapsule is:
[0085] The polyethylene glycol microcapsules wrapped with the internal disintegrant are mixed with hydroxypropyl cellulose and reacted to obtain a modified product. The weight ratio of the polyethylene glycol microcapsules wrapped with the internal disintegrant to cellulose acetate is 3:1. The diameter of the modified polyethylene glycol microcapsules is 8 microns.
[0086] Comparative Example 1:
[0087] A voriconazole dispersible tablet has the following formula: 26 parts of voriconazole, 5 parts of povidone, 18 parts of stevioside, 13 parts of cross-linked povidone, 5.25 parts of sodium bicarbonate, 1.75 parts of sodium carbonate and 7 parts of citric acid.
[0088] Prepared by the following method:
[0089] (1) micronizing the voriconazole raw material;
[0090] (2) passing stevioside and crospovidone through a 60-mesh sieve respectively;
[0091] (3) According to the weight ratio, 26 parts of the treated voriconazole, 18 parts of stevioside, 13 parts of cross-linked polyvinylpyrrolidone, 5.25 parts of sodium bicarbonate, 1.75 parts of sodium carbonate, and 7 parts of citric acid were added into a high-efficiency wet granulator and mixed evenly;
[0092] (4) Add 5 parts of povidone to prepare a soft material, then pass through a 70-mesh sieve to prepare wet granules, place the wet granules in a dryer for drying at 60° C. for 1 hour, and granulate the granules; then place the granules in a multi-directional motion mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0093] Comparative Example 2:
[0094] A voriconazole dispersible tablet has the following formula: 26 parts of voriconazole, 5 parts of povidone, 18 parts of stevioside, 13 parts of cross-linked povidone, and 7 parts of polyethylene glycol microcapsules; the sum of the weight parts of sodium bicarbonate and sodium carbonate encapsulated inside the polyethylene glycol microcapsules is 7 parts, including 5.25 parts of sodium bicarbonate and 1.75 parts of sodium carbonate; and 7 parts of citric acid are encapsulated outside the polyethylene glycol microcapsules.
[0095] Prepared by the following method:
[0096] (1) micronizing the voriconazole raw material;
[0097] (2) passing stevioside and crospovidone through a 60-mesh sieve respectively;
[0098] (3) according to the weight ratio, 26 parts of the treated voriconazole, 18 parts of stevioside, 13 parts of cross-linked polyvinylpyrrolidone, and polyethylene glycol microcapsules were added into a high-efficiency wet granulator and mixed evenly;
[0099] (4) Add 5 parts of povidone to prepare a soft material, then pass through a 70-mesh sieve to prepare wet granules, place the wet granules in a dryer for drying at 60° C. for 1 hour, and granulate the granules; then place the granules in a multi-directional motion mixer for mixing and tableting to obtain voriconazole dispersible tablets.
[0100] The preparation method of polyethylene glycol microcapsules is as follows:
[0101] According to weight parts, polyethylene glycol (molecular weight 10000) is heated to 50°C to completely melt, and 3.5 parts of sodium bicarbonate, sodium carbonate and cross-linked polyvinylpyrrolidone are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture;
[0102] The mixture is cooled to room temperature, crushed to 85 meshes, and then citric acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and citric acid wrapped outside.
[0103] Comparative Example 3:
[0104] The difference between this comparative example and Example 1 is that the polyethylene glycol microcapsules do not contain an internal disintegrant.
[0105] Verification experiment:
[0106] 1. Disintegration investigation
[0107] According to the general rule 0921 of the disintegration time limit test method of the 2020 edition of the "Chinese Pharmacopoeia", the disintegration performance test of the voriconazole dispersible tablets prepared in Examples 1 to 4 and Comparative Examples 1 to 3 was carried out. The test results are shown in Table 1:
[0108] Table 1: Disintegration time test results
[0109]
[0110] As can be seen from Table 1, in Comparative Example 1, since sodium bicarbonate, sodium carbonate and citric acid are directly added, the acid and the base are in direct contact, and when they meet water, they react rapidly to generate carbon dioxide. The disintegration time of Comparative Example 2 is slightly shorter than that of each embodiment, and the disintegration time of Comparative Example 3 is slightly longer than that of each embodiment, but the difference is not large.
[0111] 2. Dissolution test
[0112] According to the 2020 edition of the "Chinese Pharmacopoeia" dissolution and release determination method (General Rule 0931 Second Method), using 0.1 mol / L hydrochloric acid solution as the dissolution medium and a rotation speed of 50 rpm, the dissolution of voriconazole dispersible tablets prepared in Examples 1 to 4 and Comparative Examples 1 to 3 was tested. The test results are shown in Table 2:
[0113] Table 2 Dissolution test results
[0114]
[0115]
[0116] As can be seen from Table 2, due to the excessively fast disintegration rate of Comparative Example 1, the dissolution rate reached 100% at 20 min, while the dissolution rate of Comparative Example 2 was not much different from that of the embodiments. The dissolution time used in Comparative Example 3 was slightly longer, but the dissolution rate also reached 100% at 30 min, which was not much different from that of the embodiments.
[0117] 3. Stability inspection
[0118] (1) According to the high performance liquid chromatography method (General Chapter 0512) of the 2020 edition of the Chinese Pharmacopoeia, a high temperature test was carried out. The mixture was placed at 60°C for 30 days, and samples were taken at 0, 5, 10, 20, and 30 days to detect the content of active ingredients and total impurities. The results are shown in Tables 3 and 4:
[0119] Table 3 Active ingredient content under high temperature conditions (%)
[0120] Time (day) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Day 0 99.9 99.8 99.8 99.8 99.7 99.7 99.8 5 days 99.9 99.7 99.8 99.7 99.3 99.3 99.6 10 days 99.8 99.7 99.7 99.7 89.6 99.1 99.6 20 days 99.6 99.5 99.7 99.6 89.1 89.7 99.3 30 days 99.4 99.4 99.3 99.2 88.3 89.3 99.2
[0121] Table 4 Total impurity content under high temperature conditions (%)
[0122] Time (day) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Day 0 0.16 0.17 0.17 0.16 0.16 0.17 0.18 5 days 0.16 0.18 0.18 0.18 0.19 0.19 0.20 10 days 0.18 0.18 0.19 0.20 0.25 0.22 0.21 20 days 0.19 0.21 0.21 0.23 0.29 0.26 0.24 30 days 0.21 0.21 0.24 0.24 0.37 0.31 0.24
[0123] As can be seen from Tables 3 and 4, the content of the active ingredient in the dispersible tablets of each embodiment does not change much after being placed at high temperature for 30 days. In Comparative Example 1, since the acid and alkali are directly added, and no polyethylene glycol microcapsules are designed in Comparative Document 1, and no modification is performed, the content of the active ingredient is reduced more under high temperature conditions, and the impurities increase more. Compared with Comparative Example 1, Comparative Example 2 has polyethylene glycol microcapsules, and the content of the active ingredient is reduced less, but compared with each embodiment, the content of the active ingredient has also decreased significantly, and the impurities have increased significantly. In Comparative Example 3, polyethylene glycol microcapsules are used and modified to form a three-dimensional mesh layer structure. Although no internal disintegrant is designed in the polyethylene glycol microcapsules, the active ingredients and impurities are not affected. The stability is significantly better than that of Comparative Documents 1 and 2 at high temperatures. It can be seen that the use of polyethylene glycol microcapsules has a significant synergistic effect on the stability of dispersible tablets, and modification outside the polyethylene glycol microcapsules also significantly improves the stability of the product.
[0124] (2) According to the 2020 edition of the Chinese Pharmacopoeia, the high humidity (RH92.5%) test was carried out. The mixture was placed at room temperature for 30 days, and samples were taken at 0, 5, 10, 20, and 30 days to detect the content of active ingredients and total impurities. The results are shown in Tables 5 and 6:
[0125] Table 5 Active ingredient content under high humidity conditions (%)
[0126] Time (day) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Day 0 99.9 99.8 99.8 99.6 99.7 99.7 99.8 5 days 99.8 99.6 99.6 99.6 99.2 99.3 99.5 10 days 99.5 99.6 99.4 99.3 89.9 99.0 99.3 20 days 99.5 99.3 99.2 99.3 89.4 89.8 99.2 30 days 99.2 99.2 99.2 99.1 89.0 89.7 99.0
[0127] Table 6 Impurity content under high humidity conditions (%)
[0128] Time (day) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Day 0 0.16 0.17 0.18 0.16 0.16 0.17 0.18 5 days 0.17 0.19 0.20 0.19 0.20 0.18 0.21 10 days 0.18 0.19 0.22 0.20 0.25 0.23 0.22 20 days 0.20 0.21 0.24 0.23 0.28 0.24 0.24 30 days 0.22 0.21 0.24 0.24 0.33 0.29 0.24
[0129] As shown in Tables 5 and 6, under high humidity conditions, the dispersible tablets of each embodiment maintained good stability, while in Comparative Example 1, since the acid and base were directly added, the impurities in the product increased significantly when the humidity was high, and in Comparative Example 2, the base was wrapped with polyethylene glycol, and although the external organic acid was not modified, the increase in impurities was not as obvious as in Comparative Example 1. Although no internal disintegrant was designed in Comparative Example 3, the increase in impurities was not obvious, and the stability was basically the same as that of each embodiment.
[0130] The above specific implementation methods further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific implementation methods of the present invention and are not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A voriconazole dispersible tablet, It is characterized in that The invention comprises the following components in parts by weight: 20 to 40 parts of voriconazole, 5 to 12 parts of a binder, 15 to 20 parts of a sweetener, 5 to 15 parts of a disintegrant, and 5 to 10 parts of polyethylene glycol microcapsules, wherein the polyethylene glycol microcapsules are encapsulated with sodium bicarbonate and sodium carbonate, and the polyethylene glycol microcapsules are encapsulated with an organic acid, wherein the ratio of the sum of the parts by weight of the sodium bicarbonate and the sodium carbonate to the part by weight of the organic acid is 1:(1 to 1.5), and the ratio of the parts by weight of the sodium bicarbonate to the sodium carbonate is 3:1; The organic acid outside the polyethylene glycol microcapsule is modified to form a modified product having a three-dimensional network layer structure outside the polyethylene glycol microcapsule, and the modifier is any one of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate and cellulose propionate.
2. A voriconazole dispersible tablet according to claim 1, It is characterized in that The adhesive is one or a combination of two or more of povidone, hydroxymethyl cellulose and hydroxypropyl cellulose.
3. A voriconazole dispersible tablet according to claim 1, It is characterized in that The sweetener is stevioside.
4. A voriconazole dispersible tablet according to claim 1, It is characterized in that The disintegrant is one or a combination of two or more of sodium hydroxymethyl starch, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone.
5. A voriconazole dispersible tablet according to claim 1, It is characterized in that The average molecular weight of the polyethylene glycol is 800-20000, and the organic acid is any one of citric acid, tartaric acid, citric acid and fumaric acid or a combination of two or more thereof.
6. A voriconazole dispersible tablet according to claim 1, It is characterized in that The polyethylene glycol is also wrapped with an internal disintegrant, the weight ratio of the internal disintegrant to the sum of the weight parts of the sodium bicarbonate and the sodium carbonate is 1:(2-3), and the internal disintegrant is one or a combination of two or more of sodium hydroxymethyl starch sodium, low-substituted hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone.
7. A voriconazole dispersible tablet according to claim 1, It is characterized in that The diameter of the modified polyethylene glycol microcapsule with a three-dimensional network layer is 3 to 8 microns.
8. The voriconazole dispersible tablet according to claim 1, It is characterized in that The weight ratio of the modifier to the polyethylene glycol microcapsule is 1:2 to 1:
3.
9. A method for preparing a voriconazole dispersible tablet according to any one of claims 1 to 8, It is characterized in that The following steps are involved: (1) micronizing the voriconazole raw material; (2) Pass the sweetener and disintegrant through a 60-mesh sieve respectively; (3) adding the treated voriconazole, sweetener, disintegrant, and polyethylene glycol microcapsule into a high-efficiency wet granulator according to weight ratio and mixing them evenly; (4) adding a binder, sieving to obtain wet granules, placing in a dryer to dry, granulating, and tableting to obtain the obtained granules; The preparation method of the polyethylene glycol microcapsule is: According to weight parts, polyethylene glycol is heated to 50-60° C. to completely melt, and sodium bicarbonate, sodium carbonate, and an internal disintegrant are added to the melted polyethylene glycol and mixed uniformly to obtain a mixture; The mixture is cooled and crushed to 85-90 meshes, and then an organic acid is added to the crushed mixture according to a weight ratio and mixed evenly to obtain polyethylene glycol microcapsules with sodium bicarbonate, sodium carbonate and an internal disintegrant wrapped inside and organic acid wrapped outside.
10. The method for preparing a voriconazole dispersible tablet according to claim 9, It is characterized in that The polyethylene glycol microcapsule is mixed with a modifier and reacted to obtain a modified product.
